Under the terms of the partnership, South Korea-based Celltrion will undertake manufacturing and supply of four recombinant antibodies to iProgen. Among the four antibodies, two will be targeting
INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U.S. Food and Drug Administration (FDA) in July 2018 in combination with
Under the terms of the agreement, LakePharma will have the ability to offer Twist’s proprietary antibody discovery and optimization platforms to their existing and future biopharmaceutical customers as
These results were presented at the 25th Annual Conference of the British HIV Association (BHIVA) taking place from 2-5 April in Bournemouth, UK. Professor Chloe Orkin, Consultant Physician
QUE Oncology is developing drugs for large unmet medical needs and has already advanced clinical development of its lead drug program Q-122, through four Phase 1 trials. QUE
In this connection, the regulator approved the company’s Investigational New Drug (IND) application to begin the early stage trial for UCARTCS1. The allogeneic CAR-T therapy is based on
IFM Tre, which was launched in July 2018, is currently developing a suite of NLRP3 antagonists for the treatment of inflammatory diseases. NLRP3, which expands to NOD-, LRR-
In September 2018 the European Commission granted marketing authorization for NERLYNX (neratinib) for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast
The early-stage trial is assessing the safety and efficacy of the ipatasertib combination in patients with locally advanced or metastatic triple-negative breast cancer who previously did not receive
The CHMP recommended approval of an expanded indication of REVLIMID as combination therapy with bortezomib and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.